TD Cowen Maintains a Hold Rating on GSK plc (GSK), Sets a PT of $45

GSK plc (NYSE:GSK) is one of the best UK stocks to buy right now. On September 2, TD Cowen analyst Steve Scala maintained a Hold rating on GSK plc (NYSE:GSK) and set a price target of $45.00.

The analyst based the rating on the company’s market positioning and strategic outlook, stating that GSK plc’s (NYSE:GSK) ambitious sales target of £40 billion by 2031 primarily depends on its present market offerings with more than half of the expected sales are projected to come from already available products.

While this provides some stability, the analyst opined that this reliance on existing products brings in a degree of uncertainty, given the market dynamics and competitive landscape.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items.

It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs.

While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.